This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HealthEquity, Inc. (HQY) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Value Trader Highlights: Dream Finders Homes, Tenet Healthcare, El Pollo Loco, The Greenbrier Companies and Pediatrix Medical
by Zacks Equity Research
Dream Finders Homes, Tenet Healthcare, El Pollo Loco, The Greenbrier Companies and Pediatrix Medical have been highlighted in this Value Trader article.
5 Cheap Strong Buy Stocks: Values or Traps?
by Tracey Ryniec
These stocks have low P/E and P/S ratios and are Zacks Rank #1 (Strong Buys). But are they true values?
2 Small Cap AI Revolution Stocks for Your Watch List
by Tracey Ryniec
What are the risks, and rewards, of looking beyond NVIDIA and Super Micro Computer in the AI trade?
Compelling Reasons to Hold on to Ensign Group Stock Now
by Zacks Equity Research
ENSG drives revenue growth through advanced healthcare services, strategic acquisitions, and rental income from triple-net leases, supported by strong cash reserves and a 21-year dividend growth streak.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pediatrix Medical Group (MD) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Pediatrix Medical Group (MD) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Pediatrix Medical Stock Soars 30.5% Since Q3 Earnings Beat
by Zacks Equity Research
MD expects transformational and restructuring-related expenses to be $48 million in 2024.
MD vs. AVTR: Which Stock Is the Better Value Option?
by Zacks Equity Research
MD vs. AVTR: Which Stock Is the Better Value Option?
HealthEquity, Inc. (HQY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pediatrix Medical Group (MD) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 18.92% and 2.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pediatrix Medical Group (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MD vs. AVTR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MD vs. AVTR: Which Stock Is the Better Value Option?
Pediatrix Medical Up 45.8% in 3 Months: Is it Too Late to Jump In?
by Zacks Equity Research
MD remains one of the best-positioned pediatric service providers with favorable valuation to achieve margin improvement.
Pediatrix Medical Group (MD)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Why Is Pediatrix Medical Group (MD) Up 9.5% Since Last Earnings Report?
by Zacks Equity Research
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix Medical Group (MD) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Pediatrix Medical Group (MD) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
MD or RVTY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. RVTY: Which Stock Is the Better Value Option?
All You Need to Know About Pediatrix Medical Group (MD) Rating Upgrade to Strong Buy
by Zacks Equity Research
Pediatrix Medical Group (MD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here Is Why Bargain Hunters Would Love Fast-paced Mover Pediatrix Medical Group (MD)
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Pediatrix Medical Group (MD) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
MD or RVTY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. RVTY: Which Stock Is the Better Value Option?
Pediatrix (MD) Q2 Earnings Top on Stable Volumes, Shares Up 7.4%
by Zacks Equity Research
Pediatrix's (MD) second-quarter earnings benefit from stable patient volumes. Rising expenses act as a partial offset.
Pediatrix Medical Group (MD) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 9.68% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?